Company Overview
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.13.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -46.96% |
| 6 Months: | -72.77% |
| 3 Months: | +16.36% |
| 1 Month: | +6.67% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)56.80 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 84.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ENGN enGene Therapeutics Inc. PHARMA | 1.92 | -0.93 | $128.67M | 0.00% | -65.00% | -52.59% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jan 2023 | Apr 2023 | Jul 2023 | Jan 2024 | Apr 2024 | Jul 2024 | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 27.12M | 29.95M | 39.48M | 31.18M | 31.97M |
| Operating Income | -4.63M | -4.74M | -6.25M | -10.77M | -17.31M | -16.76M | - | -27.12M | -29.95M | -39.48M | -31.18M | -31.97M |
| EBITDA | - | - | - | - | - | - | - | -24.73M | -27.86M | -37.46M | -28.83M | -29.30M |
| Interest Expense | - | - | - | - | - | - | - | 734.00K | 758.00K | 750.00K | 732.00K | 745.00K |
| Pretax Income | - | - | - | - | - | - | - | -25.57M | -28.75M | -38.38M | -29.75M | -30.23M |
| Tax Provision | - | - | - | - | - | - | - | 240.00K | 239.00K | -497.00K | 0 | 0 |
| Net Income | -7.42M | -5.28M | -4.72M | -10.71M | -14.98M | -14.15M | - | -25.82M | -28.99M | -37.88M | -29.75M | -30.23M |
| Diluted EPS | 13.29 | 9.30 | 8.55 | 0.46 | 0.38 | 0.32 | -0.48 | -0.51 | -0.57 | - | -0.44 | -0.43 |
| R&D Expense | 3.67M | 3.21M | 3.90M | 5.64M | 9.86M | 11.55M | 19.97M | 20.21M | 22.57M | - | 22.25M | 22.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|
| Operating Income | -19.43M | -26.06M | -62.30M | -123.17M |
| Net Income | -24.46M | -99.92M | -55.14M | -117.30M |
| Diluted EPS | 44.30 | 151.22 | 1.46 | 2.29 |
| R&D Expense | 15.47M | 16.46M | 38.31M | 94.48M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 23.91M | 86.96M | 311.17M | 221.47M |
| Total Equity | -53.44M | -76.61M | 72.49M | 272.61M | 167.71M |
| Cash & Equivalents | - | 20.43M | 81.52M | 173.00M | 50.15M |
| Total Liabilities | - | 47.41M | 14.47M | 38.56M | 53.76M |
| Current Liabilities | - | 5.10M | 5.26M | 14.66M | 31.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -17.59M | -24.74M | -48.28M | -99.24M |
| Investing Cash Flow | -153.00K | -318.00K | -125.95M | -25.14M |
| Financing Cash Flow | 27.97M | 86.15M | 265.72M | 1.52M |
| Capital Expenditure | -153.00K | -318.00K | -925.00K | -1.49M |
| Free Cash Flow | -17.75M | -25.06M | -49.21M | -100.72M |
| Dividends Paid | - | 0 | - | - |
Ratios (Annual)
Figures in %.
| Metric | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 31.9% | -137.8% | -20.2% | -69.9% |
| ROCE % | -103.3% | -31.9% | -21.0% | -65.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FCPM III Services B.V. | 14.37% | 9.63M | $18.40M |
| 2 | BML Capital Management, LLC | 9.95% | 6.67M | $12.74M |
| 3 | Siren, L.L.C. | 9.34% | 6.26M | $11.95M |
| 4 | Perceptive Advisors Llc | 7.20% | 4.82M | $9.21M |
| 5 | Ameriprise Financial, Inc. | 3.99% | 2.68M | $5.11M |
| 6 | Nextech Invest, Ltd. | 3.47% | 2.32M | $4.44M |
| 7 | Adar1 Capital Management, LLC | 3.14% | 2.10M | $4.02M |
| 8 | Vestal Point Capital, LP | 2.49% | 1.67M | $3.18M |
| 9 | Acorn Capital Advisors, LLC | 1.90% | 1.27M | $2.43M |
| 10 | Peapod Lane Capital LLC | 1.64% | 1.10M | $2.11M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ENGN
A bladder cancer treatment study reported complete responses in 54% of patients - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQcVl5N0diX0tDUHAzVWV2WEVSN0xGUUVpVHlFRHpXRUg4MVFQTTQwYWlGU3lCVGpEWUtpUUxKWXEyejlpd0Exbk5pSXUwQmRnbE12b1lpdVE4ckU4N1YwVWM5bDNQQ2pQS0NPM3ZiM0tobzNKSmdadkctOWFCT1pvZXUyaHVoaF9vREhkTX…
A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal Investigations - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNdDFzTjhsV2hUcFNyNFZ3aml3WlVnbTRrZUJoazFEcnNoTUNnV1BzbVByNjJ4VWZvN1VqaDM1RTVjMWVDRWx4WnRKR2dwZWRYM0tYV1BUc1g4NzdCUW1Rc0pDRzA4T2lUcGZvdVhiV20xUDFCRGhTOEZ2NElNUDJOMl9FWWQyWmtPVEZqcE…
StockWatch: enGene Shares Crater on Declines in Complete Response Rates to Bladder Cancer Therapy - Genetic Engineering and Biotechnology News
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQckJPbktGUTRBVXBKREx4ZXhWTjdBY3FHaUYxTnVoTk81d1pBMjNKV2lubWlPakFyUUpKV1RfYTBCUld2NzlxSXRtYUp2RzY2c0RpS01wSjRwNVhYZnlQamxrc2lOcG5CaU9vTWlCT0J0aVNRZnVBcmJRYS1wUFl3dEN2c2ZrcFlWVnN0UW…
ENGN Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9GM1puSWlFYk5aM0QzUjBSZnRrVG01NUZsbTl1TU5hVTctS0tlOXlNX1VlRE8ycmhfOTlmV3IwNWU2SFBwTXNVUmFoZ2JkWXR4Qlo4UnVzV05xa0plMlBFcXdiQXc3UVY4OVJBeENINU5GMWdMQmw1VHRR?oc=5" target="_blank">ENG…
enGene Therapeutics: The Market Overreacted To The Latest Trial Results (NASDAQ:ENGN) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPVWFabC1mTzkwY1NKOXVuMnN4MElVX204Q19HNUw0VE1ZNllKU1J4WlViMnVITEtDc3dmeUdHVFRIUVR1SEN2eTk4b1hfdDgxVTN2VkFUUDNqLUpaQy1PejIwZ3R5alJlTUJYc3NRd2U3MnVjZ0VFRnJMeDMyM1I0MFU2SWtPai1DUGF4X0…
ENGN - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9LQW10RzVUd2lhWXpOYzdDV1hNTm1iQU1UT1cyd2EyUU9LVklGeHYyRC1jaU8tOVc5VHZkYWdtUV9YREw5M1E?oc=5" target="_blank">ENGN</a> <font color="#6f6f6f">Finviz</font>…
ENGN — Frequently Asked Questions
What is the current share price of enGene Therapeutics Inc. (ENGN)?
As of 2026-09-19 21:16 PDT, enGene Therapeutics Inc. (ENGN) trades at $1.92 on NasdaqCM. Its 52-week range is $1.44 to $12.17.
What is the market capitalisation of ENGN?
enGene Therapeutics Inc. (ENGN) has a market capitalisation of $128.67M on NasdaqCM.
What is the P/E ratio of ENGN?
ENGN trades at a trailing price-to-earnings (P/E) ratio of -0.93. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.57.
What is the return on equity (ROE) of ENGN?
ENGN has a return on equity (ROE) of -52.59%. Its return on capital employed (ROCE) is -65.00%.
Is ENGN a good stock to buy?
This page provides a data-driven analysis of enGene Therapeutics Inc. (ENGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.